Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Enara Health vs REMEVi

Enara Health
Graded #221

Lower grade

vs+8.200000000000003
REMEVi
Graded #70

Higher grade

The verdict

REMEVi takes it — 73.5/100 to 65.3/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueREMEVi +12
45
57
Dose & formulationREMEVi +30
53
83
Clinical oversightEnara Health +6
92
86
Labs & monitoringEnara Health +30
85
55
FulfillmentREMEVi +31
66
97
Contract termsREMEVi +14
55
69
Enara Health · left barREMEVi · right bar

The numbers

MetricEnara HealthREMEVi
WeighScore65.3/10073.5/100
GradeCC
Scorecard rank#221#70
SemaglutideNot disclosed$219/mo
TirzepatideNot disclosed$319/mo
Coverage6 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
Enara Health

Graded #221 · C

Strengths

  • Prescribes FDA-approved branded GLP-1s (Wegovy, Zepbound) not compounded
  • Insurance-based with prior-auth coverage for over 65% of members
  • Board-certified obesity-medicine physicians
  • Comprehensive program: dietitian, coaching, metabolic and genetic testing
  • Established since 2015 with clinical track record

Where it loses points

  • Available in only six states via partner clinics
  • Requires in-network insurance; not a flat cash-pay option
  • Not a pure-telehealth nationwide service
  • Out-of-pocket cost varies by insurance coverage
  • No compounded budget alternative for the uninsured
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard